Pathological Complete Remission of XXXX Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.

@entity1 @entity788 @entity1124 @entity5 @entity3 @entity136
UNASSIGNED: In spite of controversial issues, pancreatectomy following neoadjuvant chemoradiation therapy (NeoCRT) has been applied in treating advanced @entity788 . Cases of pathological complete remission (pCR) following NeoCRT is rare, and its long-term follow-up data are still lacking.From January 2000 to December 2012, medical records of the @entity1 who underwent pancreatectomy for @entity1124 were retrospectively reviewed. Characteristics of the @entity1 with pCR were summarized and their long-term follow-up data were analyzed.Among 86 @entity1 with @entity788 who underwent radical pancreatectomy following NeoCRT, 10 @entity1 (11.6%) were reported to pCR. Nine out of 10 @entity1 received @entity136 -based chemoradiation therapy. Median pre-NeoCRT serum CA 19-9 was 313.5U/ml, and post-NeoCRT serum CA 19-9 was 9.9U/ml, which was shown to be significant difference between 2 serum CA 19-9 level (P=0.005). Pylorus-preserving pancreaticoduodenectomy was done in 8 @entity1 , and the others received distal pancreatosplenectomy. Postoperative chemotherapy was received in 6 @entity1 . Disease-free survival was statistically superior in @entity1 with pCR than @entity1 without pCR (P<0.05). However, 5 @entity1 experienced @entity5 recurrence and no clinicopathologic variables including preoperative resectability could not predict the potential recurrence of @entity5 in @entity1 with pCR (P>0.05).pCR is rarely reported following NeoCRT, but this condition is not telling the cure of the disease. Early recurrence in the pattern of liver @entity3 and peritoneal seeding can be expected. However, long-term survival could be maintained in @entity1 without recurrence. Further investigation is necessary for predicting failure of treatment.
